Document is current

Article History

Received: 13 March 2021

Accepted: 28 September 2021

First Online: 8 October 2021

Declarations

:

: Alberto Hernando-Calvo reports travel grants from Kyowa Kirin, Merck Serono, MSD and Bristol Myers. Dave Cescon reports Consulting/Advisory: Agendia, AstraZeneca, Dynamo Therapeutics, Exact Sciences, GlaxoSmithKline, Merck, Novartis, Pfizer, Puma Biotechnology, and Roche. Research funding to institution: GlaxoSmithKline, Pfizer, and Roche. Patent (US62/675,228) for methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene. Philippe Bedard reports consulting or advisory role with Seattle Genetics, Lilly, Amgen, Merck, BMS (institution) and Pfizer (institution). Research funding from Bristol-Myers Squibb (institution), Sanofi (institution), Astrazeneca (institution), Genentech/Roche (institution) Servier (institution), GlaxoSmithKline (institution), Novartis(institution), PTC Therapeutics (institution), Nektar (institution), Merck (institution), Merck (institution), Seattle Genetics (institution) Mersana (institution), Immunomedics (institution), Lilly (institution), Amgen (institution) and Bicara (institution).

: NA.

: Additional declarations for articles in life science journals that report the results of studies involving humans and/or animals.

: All the authors have consented to participate in this review.

: All the authors have consented to participate in this review and confirmed consent for publication.